Current Hematologic Malignancy Reports

, Volume 1, Issue 3, pp 141–151 | Cite as

Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate

Article

Abstract

Imatinib (imatinib mesylate, Gleevec® [formerly known as STI571], Novartis Pharmaceuticals, Basel, Switzerland) is a protein tyrosine kinase inhibitor that is approved by the US Food and Drug Administration for patients with all phases of chronic myeloid leukemia (CML). Imatinib is remarkably effective as treatment for CML in the chronic phase (at a dosage of 400 mg/d) and the accelerated phase (at 600 mg/d). At this time, it remains to be seen whether the chronic phase of CML can be extended sufficiently in some patients so that they are functionally "cured," and also whether the increased rate of major molecular response induced by doses of imatinib higher than 400 mg/d will further improve overall survival of patients with CML in the chronic phase. The value of molecular monitoring of response in patients with CML in the chronic phase is examined. Although imatinib 800 mg/d can induce dramatic responses in patients with myeloid blast crisis, lymphoid blast crisis, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the responses are usually incomplete and of short duration. We discuss the role of imatinib in relation to allogeneic stem cell transplantation (particularly in younger patients), recognizing that the data upon which any decisions can be made are relatively immature. Finally, recent data on new tyrosine kinase inhibitors capable of overcoming primary or acquired resistance to imatinib are reviewed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Savage DG, Antman KH: Imatinib mesylate—a new oral targeted therapy. N Engl J Med 2002, 346:683–693.PubMedCrossRefGoogle Scholar
  2. 2.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056.This is the first reported case of the successful treatment of a gastrointestinal stromal tumor (GIST) with imatinib.PubMedCrossRefGoogle Scholar
  3. 3.
    Magnusson MK, Meade KE, Brown KE, et al.: Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. Blood 2001, 98:2518–2525.PubMedCrossRefGoogle Scholar
  4. 4.
    Ross TS, Bernard OA, Berger R, Gilliland DG: Fusion of Huntingtin interacting protein 1 to platelet-derived growth factor beta receptor (PDGFβR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood 1998, 91:4419–4426.PubMedGoogle Scholar
  5. 5.
    Schwaller J, Anastasiadou E, Cain D, et al.: H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood 2001, 97:3910–3918.PubMedCrossRefGoogle Scholar
  6. 6.
    van Oosterom AT, Judson I, Verweij J, et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421–1423.This is the first reported series of patients with GISTs treated with imatinib; outstanding efficacy and lack of toxicity were demonstrated.PubMedCrossRefGoogle Scholar
  7. 7.
    Schiffer CA: STI-571: current status and future prospects. Curr Opin Investig Drugs 2001, 2:1279–1281.PubMedGoogle Scholar
  8. 8.
    Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037.This landmark article describes the earliest clinical experience with imatinib.PubMedCrossRefGoogle Scholar
  9. 9.
    Peng B, Lloyd P, Schran H: Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005, 44:879–894.PubMedCrossRefGoogle Scholar
  10. 10.
    Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645–652.This article describes powerfully convincing phase II data on over 500 patients with advanced CML in the chronic phase who were treated with 400 mg/d of imatinib.PubMedCrossRefGoogle Scholar
  11. 11.
    Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530–3539.This account of a large phase II trial describes in detail the efficacy and toxicity of imatinib in over 250 patients with CML in myeloid blast crisis.PubMedCrossRefGoogle Scholar
  12. 12.
    Talpaz M, Silver RT, Druker BJ, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928–1937.This important trial of 235 patients with CML in the accelerated phase demonstrated the superior efficacy of 600 mg/d of imatinib, compared with 400 mg/d.PubMedCrossRefGoogle Scholar
  13. 13.
    Kantarjian HM, Cortes J, O’Brien S, et al.: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002, 99:3547–3553.PubMedCrossRefGoogle Scholar
  14. 14.
    Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971.This article presents data on 56 patients with either Ph+ ALL or CML with lymphoid blast crisis, confirming similar limitations of imatinib treatment in this patient group as compared with patients with myeloid blast crisis.PubMedCrossRefGoogle Scholar
  15. 15.
    Brouard M, Saurat JH: Cutaneous reactions to STI571 [letter]. N Engl J Med 2001, 345:618–619.PubMedCrossRefGoogle Scholar
  16. 16.
    Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038–1042.This landmark article is the first published report describing the efficacy of imatinib in treating Philadelphia chromosome-positive acute leukemic processes.PubMedCrossRefGoogle Scholar
  17. 17.
    Leis JF, Stepan DE, Curtin PT, et al.: Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 2004, 45:695–698.PubMedCrossRefGoogle Scholar
  18. 18.
    Shimoni A, Kroger N, Zander AR, et al.: Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003, 17:290–297.PubMedCrossRefGoogle Scholar
  19. 19.
    Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ: Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood 2000, 96:3195–3199.PubMedGoogle Scholar
  20. 20.
    Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.PubMedCrossRefGoogle Scholar
  21. 21.
    Emmanouilides C, Sawyers C, Shah N, Territo M: Successful long-term outcome of CML blast crisis with sequence of Gleevec, autologous BM transplant, and alpha-IFN/Gleevec maintenance [abstract]. Blood 2001, 98:257b.CrossRefGoogle Scholar
  22. 22.
    Shin HJ, Chung JS, Cho GJ: Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2005, 36:917–918.PubMedCrossRefGoogle Scholar
  23. 23.
    le Coutre P, Kreuzer KA, Massenkeil G, et al.: Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML [letter]. Leukemia 2003, 17:2525–2526.PubMedCrossRefGoogle Scholar
  24. 24.
    Prebet T, Tigaud I, Hayette S, et al.: Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients presenting a cytogenetic resistance to imatinib. Haematologica 2005, 90(Suppl):ECR36.PubMedGoogle Scholar
  25. 25.
    Dunlop LC, Powles R, Singhal S, et al.: Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996, 17:365–369.PubMedGoogle Scholar
  26. 26.
    Fischer T, Reifenrath C, Hess GR, et al.: Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/ablpositive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT). Leukemia 2002, 16:1220–1228.PubMedCrossRefGoogle Scholar
  27. 27.
    Tabata S, Ohno T, Tomo K, et al.: [Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia] [Japanese]. Rinsho Ketsueki 2003, 44:313–317.PubMedGoogle Scholar
  28. 28.
    Cervantes F, Hernandez-Boluda JC, Odriozola J, et al.: Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. Br J Haematol 2003, 120:500–504.PubMedCrossRefGoogle Scholar
  29. 29.
    Olavarria E, Craddock C, Dazzi F, et al.: Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002, 99:3861–3862.PubMedCrossRefGoogle Scholar
  30. 30.
    Silver RT, Talpaz M, Sawyers CL, et al.: Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 23.Google Scholar
  31. 31.
    O’Dwyer ME, Mauro MJ, Kurilik G, et al.: The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002, 100:1628–1633.PubMedCrossRefGoogle Scholar
  32. 32.
    Cortes JE, Talpaz M, Giles F, et al.: Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003, 101:3794–3800.PubMedCrossRefGoogle Scholar
  33. 33.
    Gambacorti C, Talpaz M, Sawyers CL, et al.: Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-α [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1089.Google Scholar
  34. 34.
    O’Brien SG, Guilhot F, Larson R A, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994–1004.This study established imatinib as the new standard front-line treatment for chronic-phase CML, as patients randomized to imatinib had a significantly higher rate of cytogenetic remission and (more importantly) a lower rate of progression to accelerated or blast phase as compared with patients receiving interferon and cytarabine.PubMedCrossRefGoogle Scholar
  35. 35.
    Goldman JM, Hughes T, Radich J, et al.: Continuing reduction in level of residual disease af ter 4 years in patients with CML in chronic phase responding to f irst-line imatinib (IM) in the IRIS study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 163.Google Scholar
  36. 36.
    Poerio A, Amabile M, Iacobucci I, et al.: Better molecular response (MR) to imatinib (IM) in early chronic phase (CP) versus late CP chronic myeloid leukemia (CML) patients (pts) in complete cytogenetic dyresponse (CCR): a comparison at 24 months of 2 clinical trials of the GIMEMA Working Party on CML on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia (GIMEMA-CML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1096.Google Scholar
  37. 37.
    Guilhot F: Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatiniy(IM) therapy: update from the IRIS study [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:Abstract 21.This oral presentation at ASH 2004 provided updated data on the durability of clinical responses to imatinib, particularly in patients who achieved an early major cytogenetic response.Google Scholar
  38. 38.
    Le Gouill S, Talmant P, Milpied N, et al.: Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 2000, 18:1533–1538.Google Scholar
  39. 39.
    Medina J, Kantarjian H, Talpaz M, et al.: Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003, 98:1905–1911.PubMedCrossRefGoogle Scholar
  40. 40.
    Loriaux M, Deininger M: Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004, 45:2197–2203.PubMedCrossRefGoogle Scholar
  41. 41.
    Lange T, Bumm T, Otto S, et al.: Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004, 89:49–57.PubMedGoogle Scholar
  42. 42.
    Deininger MWN: Management of early stage disease. Hematology (Am Soc Hematol Educ Program) 2005, 174–182.Google Scholar
  43. 43.
    Angstreich GR, Matsui W, Huff CA, et al.: Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 2005, 130:373–381.PubMedCrossRefGoogle Scholar
  44. 44.
    Rousselot P, Huguet F, Cayuela JM, et al.:Imatinib mesylate discontinuation in patients with chronic myelogenous leukaemia in complete molecular remission for more than two years [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1101.Google Scholar
  45. 45.
    Zonder JA, Pemberton P, Brandt H, et al.: The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003, 9:2092–2097.PubMedGoogle Scholar
  46. 46.
    Kantarjian HM, Talpaz M, O’Brien S, et al.: Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003, 101:473–475.PubMedCrossRefGoogle Scholar
  47. 47.
    Lee F Y, Wen ML, Bhide R, et al.: Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1994.Google Scholar
  48. 48.
    Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399–401.This in vitro study demonstrated that dasatinib can overcome resistance to imatinib conferred by mutations in BCR-ABL.PubMedCrossRefGoogle Scholar
  49. 49.
    Sawyers CL, Kantarjian H, Shah N, et al.: Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase I study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 38.This abstract describes the earliest clinical experience with dasatinib, a more potent tyrosine kinase inhibitor. It demonstrates efficacy against imatinib-resistant CML at all stages.Google Scholar
  50. 50.
    Hochhaus A, Baccarani M, Sawyers C, et al.: Efficacy of dasatinib in patients with chronic phase Philadelphia chromosome-positive CML resistant or intolera imatinib: first results of the CA180013 ‘START-C’ phase II study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 41.Google Scholar
  51. 51.
    Talpaz M, Rousselot P, Kim DW, et al.: A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in myeloid blast crisis who are resistant or intoleranto imatinib: first results of the CA180006 ‘START-B’ study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 40.Google Scholar
  52. 52.
    Ottmann OG, Martinelli G, Dombret H, et al.: A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphiachromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: the ‘START-L’ CA180015 study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 42.Google Scholar
  53. 53.
    Guilhot F, Apperley JF, Shah N, et al.: A phase II study of dasatinib in patients with accelerated phase chronic myeloid leukemia (CML) who are resistant or intolera to imatinib:first results of the CA180005 ‘START-A’ study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 39.Google Scholar
  54. 54.
    O’Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500–4505.PubMedCrossRefGoogle Scholar
  55. 55.
    Kantarjian HM, Ottman O, Cortes J, et al.: AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph+ ALL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 37.Google Scholar
  56. 55a.
    Kantarjian HM, Gattermann N, O’Brien SG, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). J Clin Oncol 2006, 24:18S. Abstract 6534.CrossRefGoogle Scholar
  57. 55b.
    Giles FJ, Larson R, Le Coutre P, et al.: A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Paper presented at 2006 ASCO Annual Meeting. Atlanta, GA; June 2–6, 2006. Abstract 6536.Google Scholar
  58. 55c.
    Le Coutre PD, Ottmann O, Gatterman N, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). J Clin Oncol 2006, 24:18S. Abstract 6531.CrossRefGoogle Scholar
  59. 56.
    Reiter E, Greinix HT, Keil F, et al.: Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol 1999, 78:507–513.PubMedCrossRefGoogle Scholar
  60. 57.
    Jabbour E, Cortes J, Talpaz M, et al.: Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson Cancer Center (MDACC) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1091.Google Scholar
  61. 58.
    Branford S, Hughes T, Nicoll J, et al.: Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients: impact and fate of imatinib-resistant clones in dasatinib-treated patients [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 437.Google Scholar
  62. 59.
    Kantarjian H, Talpaz M, O’Brien S, et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873–2878.PubMedCrossRefGoogle Scholar
  63. 60.
    Cortes J, Talpaz M, O’Brien S, et al.: A randomized trial of high-dose (HD) imatinib mesylate (IM) with or without peg-interferon (PEG-IFN) and GM-CSF as frontline therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1084.Google Scholar
  64. 61.
    Berger U, Hochhaus A, Pfirrmann M, et al.: Concept, feasibility and results of the randomized comparison of imatinib combination therapies for chronicact]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1083.Google Scholar
  65. 62.
    Oki Y, Kantarjian HM, O’Brien S, et al.: Phase II study of decitabine in combination with imatinib mesylate in patients with accelerated (AP) or blastic phase (BP) of chronic myeloid leukemia (CML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1099.Google Scholar
  66. 63.
    Radujkovic A, Topaly J, Zeller WJ, et al.: Treatment of imatinib-sensitive and -resistant chronic myelogenous leukemia cells with a combination of imatinib and farnesyltransferase inhibitors [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, pp106:Abstract 4881.Google Scholar
  67. 64.
    Copland M, Hamilton A, Allan EK, et al.: BMS-214662 targets quiescent chronic myeloid leukaemia stem cells and enhances the activity of both imatinib and dasatinib (BMS-354825) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 693.Google Scholar
  68. 65.
    Wetzler M, Yu D, Odenike O, et al.: Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia (CML)—Cancer and Leukemia Group B Study 10107 [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1097.Google Scholar
  69. 66.
    Grifin JD, Weisberg EL: Simultaneous administration of AMN107 and imatinib in the treatment of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 694.Google Scholar
  70. 67.
    Radujkovic A, Schad M, Topaly J, et al.: Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL—inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005, 19:1198–1206.PubMedCrossRefGoogle Scholar
  71. 68.
    Bocchia M, Abruzzese E, Ippoliti M, et al.: Control of residual disease in imatinib treated chronic myeloid leukemia patients with peptide vaccinations: 2 years follow up of CMLVAX100 Trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 167.Google Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Hematology/Oncology, Karmanos Cancer InstituteWayne State University School of MedicineDetroitUSA

Personalised recommendations